- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT02731885
Food Effect on Pharmacokinetic Parameters of ABX464
An Open, Randomized Study, to Investigate the Potential Food Effect on Pharmacokinetic Parameters of ABX464 Administered Orally to Healthy Male Subjects
Panoramica dello studio
Stato
Condizioni
Intervento / Trattamento
Descrizione dettagliata
This is a phase I, single-center, open-label, two-treatment, food-effect, randomized study in 40 healthy Caucasian male subjects in order to determine the impact of the food on the absorption of the ABX464.
The two different treatments are the followings:
- Treatment A = 50mg of ABX464 (two 25mg capsules) /Fasted
- Treatment B = 50mg of ABX464 (two 25mg capsules) / Fed
This study consists of two groups:
- Group 1 - single dose assessments, two-period, two-treatment, cross-over: 20 subjects will receive a single dose of 50mg of ABX464 in fed and fasted condition, separated by a wash-out period of at least 45 days.
- Group 2 - multiple dose assessments: 20 subjects will receive 50mg of ABX464 every 3 days during 10 days in fasted or fed condition.
Tipo di studio
Iscrizione (Effettivo)
Fase
- Fase 1
Contatti e Sedi
Luoghi di studio
-
-
Phoenix
-
Sayed Hossen road, Phoenix, Maurizio
- CAP Research
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- Healthy Caucasian male subjects, 18-55 years of age
- Body Mass Index (BMI) of 17-28 kg/m².
- Certified as healthy by a comprehensive clinical assessment (detailed medical history and complete physical examination)
Normal vital signs after 10 minutes resting in supine position:
90 mmHg < systolic blood pressure < 140 mmHg, 50 mmHg < diastolic blood pressure < 90 mmHg, 40 bpm < heart rate < 100 bpm.
- Normal automatic 12-lead ECG (incomplete right bundle branch block can be accepted) or judged as non clinically significant.
- Clinical laboratory tests (hematology, blood chemistry, and urinalysis) must be within normal limits or clinically acceptable to Investigator and Sponsor.
- Subjects must be willing to give written informed consent prior to study enrollment and be able to adhere to restrictions and examination schedules.
Exclusion Criteria:
- Individuals with a history of any significant medical disorder which requires a physician's care (cardiovascular, pulmonary, gastro-intestinal, hepatic, renal, metabolic, hematological, neurologic, psychiatric, systemic, or infectious disease; any acute infectious disease or signs of acute illness)
- Frequent headaches and / or migraine, recurrent nausea and / or vomiting (more than twice a month).
- Presence or history of drug allergy, or allergic disease diagnosed and treated by a physician.
- Individuals who have a history of any clinically significant local or systemic infectious disease within 4 weeks prior to drug administration.
- Any individual who does not comply with the requirement that he should not have used any drugs other than paracetamol for at least 2 weeks prior to the study nor alcohol within 48 hours prior to drug administration.
- Individuals who are positive for hepatitis B virus, hepatitis C virus or HIV.
- History or presence of drug or alcohol abuse (positive urine drug screen, positive alcohol breath test).
- Smoking more than 5 cigarettes or equivalent / day, unable to stop smoking during the study.
- Excessive consumption of beverages with xanthine bases (> 4 cups or glasses / day).
- Subject who will likely be unable to eat entirely the standard high fat breakfast within the allocated time.
- Individuals who have donated blood within the preceding 3 months.
- Individuals who refuse to use an effective method of contraception from the beginning of the study and until 3 months after dosing.
- Individuals with forfeiture of freedom by an administrative or legal obligation or under guardianship
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione incrociata
- Mascheramento: Nessuno (etichetta aperta)
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Sperimentale: Fasted Conditions
50mg of ABX464 (two 25mg capsules) /Fasted
|
Two-periods, subjects received a single dose of 50mg of ABX464 in fed and fasted condition, separated by a wash-out period of at least 45 days.
Subjects received 50mg of ABX464 every 3 days during 10 days in fasted or fed condition.
|
|
Sperimentale: Fed Conditions
50mg of ABX464 (two 25mg capsules) /Fed
|
Two-periods, subjects received a single dose of 50mg of ABX464 in fed and fasted condition, separated by a wash-out period of at least 45 days.
Subjects received 50mg of ABX464 every 3 days during 10 days in fasted or fed condition.
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Lasso di tempo |
|---|---|
|
Area under the plasma concentration versus time curve (AUC) of single oral dose of 50mg of ABX464 in fed or fasted condition.
Lasso di tempo: 45 days
|
45 days
|
|
Peak Plasma Concentration (Cmax) of single oral dose of 50mg of ABX464 in fed or fasted condition.
Lasso di tempo: 45 days
|
45 days
|
Misure di risultato secondarie
Misura del risultato |
Lasso di tempo |
|---|---|
|
Area under the plasma concentration versus time curve (AUC) of repeated doses of 50 mg of ABX464 in fed or fasted conditions
Lasso di tempo: 10 days
|
10 days
|
|
Peak Plasma Concentration (Cmax) of repeated doses of 50 mg of ABX464 in fed or fasted conditions
Lasso di tempo: 10 days
|
10 days
|
|
Number of Subjects with treatment-related adverse events as assessed by CTCAE v4.0
Lasso di tempo: Up to 45 days
|
Up to 45 days
|
Collaboratori e investigatori
Sponsor
Pubblicazioni e link utili
Studiare le date dei record
Studia le date principali
Inizio studio
Completamento primario (Effettivo)
Completamento dello studio (Effettivo)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Stima)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Stima)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Altri numeri di identificazione dello studio
- ABX464-FE-001
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .
Prove cliniche su ABX464 Single dose
-
Abivax S.A.CompletatoArtrite reumatoideBelgio, Francia, Ungheria, Polonia
-
Abivax S.A.CompletatoInfezioni da HIV | Volontari SanitariSpagna
-
Abivax S.A.TerminatoCOVID-19Spagna, Regno Unito, Germania, Belgio, Francia, Italia, Brasile, Messico
-
Abivax S.A.CompletatoColite ulcerosaStati Uniti, Israele, Regno Unito, Spagna, Irlanda, Nuova Zelanda, Italia, Croazia, Polonia, Bulgaria, Germania, Ungheria, Serbia, Belgio, Cechia, Giappone, Canada, Romania, India, Brasile, Slovacchia, Messico, Lituania, Francia, ...
-
Abivax S.A.CompletatoColite ulcerosaSpagna, Stati Uniti, Cina, Belgio, Australia, Austria, Italia, India, Portogallo, Bulgaria, Ungheria, Olanda, Polonia, Germania, Canada, Grecia, Francia, Cechia, Regno Unito, Svizzera, Argentina, Ucraina, Turchia (Türkiye), Corea...
-
Abivax S.A.Attivo, non reclutanteColite ulcerosaBelgio, Ungheria, Austria, Spagna, Francia, Polonia, Germania, Canada, Cechia, Italia, Slovacchia, Slovenia, Serbia, Ucraina
-
Abivax S.A.Orion Corporation, Orion PharmaCompletato
-
Abivax S.A.CompletatoColite ulcerosaPolonia, Spagna, Francia, Germania, Italia, Slovenia, Belgio, Canada, Bielorussia, Ungheria, Austria, Regno Unito, Cechia, Serbia, Slovacchia, Ucraina
-
Abivax S.A.Attivo, non reclutanteColite ulcerosaStati Uniti, Spagna, Israele, Cina, Regno Unito, Irlanda, Belgio, Australia, Austria, Olanda, Nuova Zelanda, Italia, India, Portogallo, Bulgaria, Ungheria, Polonia, Croazia, Germania, Serbia, Canada, Grecia, Francia, Cechia, Argen... e altro ancora